Allworth Financial
TRDA icon

Allworth Financial’s Entrada Therapeutics TRDA Stock Holding History

Allworth Financial’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.76K Buy
647
+338
+109% +$3.24K ﹤0.01% 4142
2026
Q1 		$3.9K Buy
+309
New +$3.54K ﹤0.01% 4096
2025
Q3 		– Sell
-62
Closed -$417 – 5047
2025
Q2 		$417 Buy
62
+26
+72% +$209 ﹤0.01% 4182
2025
Q1 		$323 Buy
+36
New +$449 ﹤0.01% 3782

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Allworth Financial's TRDA Position: Q2 2026 in Review

Allworth Financial increased its Entrada Therapeutics (TRDA) stake by 109% in Q2 2026, buying an estimated $3.24K and bringing the position to 647 shares worth $4.76K. The position accounts for ﹤0.01% of the portfolio, ranked #4142.

Allworth Financial first reported a position in TRDA in Q1 2025 and has held it in 4 quarters since. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Allworth Financial held 647 shares of Entrada Therapeutics worth $4.76K as of Q2 2026.
  • Allworth Financial bought 338 Entrada Therapeutics shares in Q2 2026, an estimated $3.24K.
  • Entrada Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #4142 holding.
  • Allworth Financial first reported a position in Entrada Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.